Financials in USD. Standardized financial statements.
A compact view of how CTI BioPharma Corp. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $53.95M | $0 | $0 | $3.35M | $26.29M | $25.15M | $57.41M | $16.12M | $60.08M | $34.68M |
| Revenue Growth? | 0.0% | 0.0% | -100.0% | -87.3% | +4.5% | -56.2% | +256.2% | -73.2% | +73.2% | 0.0% |
| Cost of Revenue? | $3.51M | $161,000 | $4.20M | $0 | $879,000 | $364,000 | $1.38M | $1.94M | $895,000 | $137,000 |
| Gross Profit? | $50.43M | -$161,000 | -$4.20M | $3.35M | $25.41M | $24.78M | $56.03M | $14.18M | $59.18M | $34.54M |
| Gross Margin? | +93.5% | 0.0% | 0.0% | +100.0% | +96.7% | +98.6% | +97.6% | +88.0% | +98.5% | +99.6% |
| Operating Expenses? | $130.23M | $95.33M | $47.77M | $43.26M | $57.65M | $64.30M | $105.19M | $130.84M | $145.41M | $75.91M |
| Operating Income? | -$79.80M | -$95.33M | -$47.77M | -$40.71M | -$32.90M | -$39.52M | -$49.16M | -$116.67M | -$86.23M | -$41.53M |
| EBITDA? | -$79.85M | -$95.33M | -$51.22M | -$37.42M | -$32.90M | -$39.52M | -$49.16M | -$116.67M | -$86.23M | -$39.63M |
| Income Before Tax | -$92.99M | -$97.91M | -$52.45M | -$40.02M | -$29.35M | -$40.83M | -$52.95M | -$120.76M | -$94.23M | -$43.55M |
| Income Tax Expense | -$1.95M | $1.73M | $500,000 | $2.29M | $5.28M | $723,000 | -$963,000 | -$1.60M | -$5.32M | -$485,000 |
| Net Income? | -$91.04M | -$99.64M | -$52.95M | -$42.32M | -$29.32M | -$40.67M | -$52.01M | -$119.42M | -$93.37M | -$42.74M |
| EPS? | $-0.79 | $-1.11 | $-0.74 | $-0.73 | $-0.52 | $-1.12 | $-1.86 | $-4.26 | $-6.29 | $-3.74 |
| Diluted EPS? | $-0.79 | $-1.11 | $-0.74 | $-0.73 | $-0.52 | $-1.12 | $-1.86 | $-4.26 | $-6.29 | $-3.74 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality